390157
Position
Operating Partner
Company
Clarus Funds
Location
Boston Massachusetts UNITED STATES
Bio
Paris Panayiotopoulos is the operating partner of Clarus Funds and global biopharmaceutical leader who was most recently the President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc., where he led the transformation of ARIAD into a leading rare cancer company, achieving approximately a five-fold multiple in market value in one year and the acquisition by Takeda Pharmaceuticals for $5.2 billion in February 2017. Prior to joining ARIAD in January 2016, Mr. Panayiotopoulos served as President of EMD Serono, Inc., the North American biopharmaceutical business of Merck KGaA, President of the Serono Research & Development Institute, and President of Merck Serono, Tokyo, Japan. Through a strong focus on vision, strategy, culture and execution, Mr. Panayiotopoulos turned around the company's US and Japan healthcare businesses and led a transformative global restructure, among other significant achievements. Since joining Merck KGaA in 2004, in his leadership roles across therapeutic area franchises and geographical regions, Mr. Panayiotopoulos led numerous partnerships including those with Pfizer Inc., Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co. Ltd. and Incyte Corporation. Mr. Panayiotopoulos is currently serving as a member of the Board of Directors of the Medicines Company and Corbus Pharmaceuticals, as an advisor to Clarus Ventures and Roivant Sciences, has served on the Board of BIO, EFPIA and Mass Bio, and is on the Board of Advisors of the nonprofit Life Science Cares. Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004. He is deeply interested in both science and business innovation and holds a combined B.Sc. in Chemistry and Management Studies from University College London and a M.Sc. from Cranfield Business School in the United Kingdom.
Interests
None yet.